- Home
- KALV vs RIGL Comparison
KALV vs RIGL Comparison
Compare KALV & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALV
- RIGL
- Stock Information
- Founded
- KALV N/A
- RIGL 1996
- Country
- KALV United States
- RIGL United States
- Employees
- KALV N/A
- RIGL N/A
- Industry
- KALV Biotechnology: Pharmaceutical Preparations
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- KALV Health Care
- RIGL Health Care
- Exchange
- KALV Nasdaq
- RIGL Nasdaq
- Market Cap
- KALV 551.2M
- RIGL 537.6M
- IPO Year
- KALV N/A
- RIGL 2000
- Fundamental
- Price
- KALV $13.62
- RIGL $42.26
- Analyst Decision
- KALV Strong Buy
- RIGL Buy
- Analyst Count
- KALV 8
- RIGL 6
- Target Price
- KALV $26.43
- RIGL $39.83
- AVG Volume (30 Days)
- KALV 1.2M
- RIGL 640.7K
- Earning Date
- KALV 11-10-2025
- RIGL 11-04-2025
- Dividend Yield
- KALV N/A
- RIGL N/A
- EPS Growth
- KALV N/A
- RIGL 2698.26
- EPS
- KALV N/A
- RIGL 6.20
- Revenue
- KALV $1,426,000.00
- RIGL $282,076,000.00
- Revenue This Year
- KALV N/A
- RIGL $59.93
- Revenue Next Year
- KALV $234.65
- RIGL N/A
- P/E Ratio
- KALV N/A
- RIGL $6.78
- Revenue Growth
- KALV N/A
- RIGL 79.13
- 52 Week Low
- KALV $7.30
- RIGL $14.63
- 52 Week High
- KALV $17.28
- RIGL $43.72
- Technical
- Relative Strength Index (RSI)
- KALV 70.91
- RIGL 71.17
- Support Level
- KALV $10.55
- RIGL $34.00
- Resistance Level
- KALV $13.44
- RIGL $39.56
- Average True Range (ATR)
- KALV 0.65
- RIGL 2.32
- MACD
- KALV 0.36
- RIGL 1.15
- Stochastic Oscillator
- KALV 94.79
- RIGL 97.43
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.